Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10797224
Filing Date		2004-03-10
First Named Inventor	Zhen	-Cheng Wu
Art Unit		2826
Examiner Name	Sand	tvik, Benjamin P.
Attorney Docket Number		252011-2000

				Attorn	icy DOG	KOL HUIIIDOI	232011-2000				
					U.S.I	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [sue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1	6455417		2002-0	9-24	Baoetal.					
If you wish	to a	dd additional U.S. Pater	t citatio	n inform	ation pl	lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLIC	CATION PUBL	ICATIONS		Remove	İ	_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	on Name of Patentee or Applicant of cited Document		Releva		Lines where	
	1	20020140103		2002-1	D- 0 3	Kloster et al.					
	2	20020100693		2002-0	8-01	Luetal.					
If you wish	to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		_
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Cite Foreign Document Country Number3 Code2 i			Kind Code4 Publication Date Name of Patent Applicant of cite Document		e or	vhere Rel	or Relevant	т.			
	1										Г
If you wish	to a	d additional Foreign Pa				information pl		button	Add		_
			NON	-PAIE	NI LIIE	KATUKE DO	LUMEN 15		, contove	J	

		Application Number		10797224		
	Filing Date		2004-03-10			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Zhen		n-Cheng Wu		
(Not for submission under 37 CFR 1.99)	Art Unit		2826			
	(Examiner Name Sand		ndvik, Benjamin P.		
		Attorney Docket Numb	er	252011-2000		

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				
	1	Taiwan Search Report issued May 24, 2006				

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINES SIGNATURE

Examiner Signature Date Considered

"EXAMINER: nitial irreference considered, whether or not citation is in conformance with MPEP 60s. Draw line through a citation if not inconformance and not considered, include copy of this form with next communication to applicant.

1 See Kind Codes of USPT/D Patient Documents at year USPT(D,QQ/ or MEEP 801.04. ² Enter office that issued the document, by the bio-oblete code (WIPD Standard ST3.) ² Sort plaquence plants chouments, be excited not fine year of the Emperor most procedure the sent number of the period tocument.

* Kind of document by the opporpriate symbols as indicated on the document under WIPD Standard ST.18 if possible. ³ Applicant is to place a check mark here if English targuages breakfalors in attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Zhen Art Unit		10797224		
		2004-03-10		
		-Cheng Wu		
		2826		
Examiner Name	Sand	vik, Benjamin P.		
Attorney Docket Number		252011-2000		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of forms foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the agriculture.							
Signature	/Daniel R. McClure/	Date (YYYY-MM-DD)	2006-07-25				
Name/Print	Daniel R. McClure	Registration Number	38962				

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, u.S. Operationed of Commence, P. 0. Bot 1450, Alexandria, V.3231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.